Casili, G.; Scuderi, S.A.; Lanza, M.; Filippone, A.; Mannino, D.; Giuffrida, R.; Colarossi, C.; Mare, M.; Capra, A.P.; De Gaetano, F.;
et al. Correction: Casili et al. Therapeutic Potential of BAY-117082, a Selective NLRP3 Inflammasome Inhibitor, on Metastatic Evolution in Human Oral Squamous Cell Carcinoma (OSCC). Cancers 2023, 15, 2796. Cancers 2024, 16, 1211.
https://doi.org/10.3390/cancers16061211
AMA Style
Casili G, Scuderi SA, Lanza M, Filippone A, Mannino D, Giuffrida R, Colarossi C, Mare M, Capra AP, De Gaetano F,
et al. Correction: Casili et al. Therapeutic Potential of BAY-117082, a Selective NLRP3 Inflammasome Inhibitor, on Metastatic Evolution in Human Oral Squamous Cell Carcinoma (OSCC). Cancers 2023, 15, 2796. Cancers. 2024; 16(6):1211.
https://doi.org/10.3390/cancers16061211
Chicago/Turabian Style
Casili, Giovanna, Sarah Adriana Scuderi, Marika Lanza, Alessia Filippone, Deborah Mannino, Raffaella Giuffrida, Cristina Colarossi, Marzia Mare, Anna Paola Capra, Federica De Gaetano,
and et al. 2024. "Correction: Casili et al. Therapeutic Potential of BAY-117082, a Selective NLRP3 Inflammasome Inhibitor, on Metastatic Evolution in Human Oral Squamous Cell Carcinoma (OSCC). Cancers 2023, 15, 2796" Cancers 16, no. 6: 1211.
https://doi.org/10.3390/cancers16061211
APA Style
Casili, G., Scuderi, S. A., Lanza, M., Filippone, A., Mannino, D., Giuffrida, R., Colarossi, C., Mare, M., Capra, A. P., De Gaetano, F., Portelli, M., Militi, A., Cuzzocrea, S., Paterniti, I., & Esposito, E.
(2024). Correction: Casili et al. Therapeutic Potential of BAY-117082, a Selective NLRP3 Inflammasome Inhibitor, on Metastatic Evolution in Human Oral Squamous Cell Carcinoma (OSCC). Cancers 2023, 15, 2796. Cancers, 16(6), 1211.
https://doi.org/10.3390/cancers16061211
